These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2457417)

  • 1. [Treatment of T3-predominant Graves' disease].
    Lin LX
    Zhonghua Yi Xue Za Zhi; 1988 Feb; 68(2):79-81. PubMed ID: 2457417
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical significance of elevated serum triiodothyronine to thyroxine ratios in patients with Graves' disease treated with antithyroid drugs].
    Takamatsu J
    Nihon Naibunpi Gakkai Zasshi; 1983 Mar; 59(3):295-303. PubMed ID: 6190686
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
    Khanna CM; Shankar LR; Jaggi CB; Bansal JK; Chugh P
    J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J; Sugawara M; Kuma K; Kobayashi A; Matsuzuka F; Mozai T; Hershman JM
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Stimulation of endogenous TSH secretion and endocrine orbitopathy].
    Wuttke H; Schlieter D
    Med Klin; 1980 Aug; 75(18):658-62. PubMed ID: 6158667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of effects of antithyroid drug treatment based mainly on the TRH test].
    Irie M; Enomoto K; Inoue K; Enomoto H; Nukii T
    Horumon To Rinsho; 1974 Feb; 22(2):249-50. PubMed ID: 4136015
    [No Abstract]   [Full Text] [Related]  

  • 10. The significance of triiodothyronine in the evaluation of thyroid function after treatment for hyperthyroidism.
    Smeulers J; Docter R; Visser TJ; Hennemann G
    Neth J Med; 1980; 23(1):18-22. PubMed ID: 6154249
    [No Abstract]   [Full Text] [Related]  

  • 11. Closer correlation between serum triiodothyronine and basal metabolic rate during antithyroid drug treatment in patients with Graves' disease.
    Hamada N; Miura T; Ban Y; Momotani N; Nishikawa Y; Ohno M; Morii H; Kitabatake S; Ito K
    Endocrinol Jpn; 1978 Apr; 25(2):117-22. PubMed ID: 78844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term antithyroid drug therapy for intractable cases of Graves' disease.
    Shizume K
    Endocrinol Jpn; 1978 Aug; 25(4):377-9. PubMed ID: 81772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness to thyrotropin releasing hormone and thyroid suppressibility in Graves' disease patients remaining in remission after antithyroid drug therapy.
    Rajatanavin R; Mahatumarat P; Poochanugool L; Kumpolpunth S; Himathongkam T
    J Med Assoc Thai; 1981 Jan; 64(1):11-8. PubMed ID: 6163837
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
    Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?
    Bogazzi F; Martino E; Bartalena L
    J Endocrinol Invest; 2003 Feb; 26(2):174-6. PubMed ID: 12739747
    [No Abstract]   [Full Text] [Related]  

  • 17. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The association of Graves' disease with serum soluble interleukin 2 receptor].
    Ren YZ; Song ZG
    Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):264-5, 317. PubMed ID: 8221241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proceedings: Effect of inorganic iodine on serum thyroxine concentration in Basedow's disease--in patients during treatment with antithyroid agents].
    Ikeda H; Imai Y; Uchimura H; Matsuzaki F; Nagataki S
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):408. PubMed ID: 4141670
    [No Abstract]   [Full Text] [Related]  

  • 20. [Endocrine ophthalmopathy in Graves disease during antithyroid drug therapy (author's transl)].
    Wuttke H; Schlieter D; Krück F
    Klin Wochenschr; 1979 Jan; 57(2):69-74. PubMed ID: 84095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.